Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AURA Aura Biosciences	$6.72 -4.0%	$6.62	$4.34 ▼ $12.38	$434.84M	0.46	162,722 shs	98,916 shs
CRVO CervoMed	$10.12 -0.7%	$7.74	$1.80 ▼ $20.63	$94.29M	-0.79	817,438 shs	120,318 shs
IVA Inventiva	$4.36 +3.3%	$3.35	$1.53 ▼ $4.36	$403.70M	0.73	26,083 shs	63,365 shs
TNXP Tonix Pharmaceuticals	$51.43 -13.7%	$41.38	$6.76 ▼ $130.00	$522.27M	1.7	1.68 million shs	4.59 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AURA Aura Biosciences	-4.00%	-1.18%	-3.31%	+12.94%	-13.62%
CRVO CervoMed	-0.69%	+2.74%	+33.51%	+15.26%	-40.61%
IVA Inventiva	+3.32%	+21.79%	+31.33%	+40.19%	+100.00%
TNXP Tonix Pharmaceuticals	-13.67%	+10.63%	+14.15%	+83.69%	+1.97%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AURA Aura Biosciences	2.3433 of 5 stars	3.6	0.0	3.2	3.3	0.0
CRVO CervoMed	2.365 of 5 stars	3.4	2.0	2.4	1.7	0.6
IVA Inventiva	3.62 of 5 stars	3.4	5.0	4.1	1.7	0.6
TNXP Tonix Pharmaceuticals	2.6198 of 5 stars	3.5	2.0	2.9	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AURA Aura Biosciences	3.25	Buy	$22.00	227.38% Upside
CRVO CervoMed	2.78	Moderate Buy	$21.43	111.74% Upside
IVA Inventiva	2.80	Moderate Buy	$10.40	138.53% Upside
TNXP Tonix Pharmaceuticals	3.00	Buy	$70.00	36.10% Upside

Current Analyst Ratings Breakdown

Latest CRVO, IVA, TNXP, and AURA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	AURA Aura Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00
8/12/2025	CRVO CervoMed	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$20.00 ➝ $16.00
8/11/2025	CRVO CervoMed	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $15.00
8/11/2025	CRVO CervoMed	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00
7/29/2025	CRVO CervoMed	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$21.00 ➝ $27.00
7/25/2025	CRVO CervoMed	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/11/2025	CRVO CervoMed	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/3/2025	TNXP Tonix Pharmaceuticals	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/28/2025	AURA Aura Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$22.00
5/23/2025	AURA Aura Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$19.00

(Data available from 8/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AURA Aura Biosciences	N/A	N/A	N/A	N/A	$2.81 per share	N/A
CRVO CervoMed	$9.74M	9.61	N/A	N/A	$3.61 per share	2.80
IVA Inventiva	$9.95M	41.92	N/A	N/A	($1.21) per share	-3.60
TNXP Tonix Pharmaceuticals	$10.09M	44.71	N/A	N/A	$19.17 per share	2.68

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AURA Aura Biosciences	-$86.92M	-$1.90	N/A	N/A	N/A	N/A	-64.44%	-54.24%	N/A
CRVO CervoMed	-$16.29M	-$2.61	N/A	N/A	N/A	-290.72%	-59.15%	-53.64%	N/A
IVA Inventiva	-$199.34M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	9/25/2025 (Estimated)
TNXP Tonix Pharmaceuticals	-$130.04M	-$39.47	N/A	N/A	N/A	-828.22%	-57.93%	-51.04%	N/A

Latest CRVO, IVA, TNXP, and AURA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	AURA Aura Biosciences	-$0.49	-$0.47	+$0.02	-$0.47	N/A	N/A
8/11/2025	Q1 2025	TNXP Tonix Pharmaceuticals	-$3.10	-$3.86	-$0.76	-$3.86	$2.60 million	$2.00 million
8/8/2025	Q2 2025	CRVO CervoMed	-$0.57	-$0.70	-$0.13	-$0.70	$1.45 million	$1.76 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AURA Aura Biosciences	N/A	N/A	N/A	N/A	N/A
CRVO CervoMed	N/A	N/A	N/A	N/A	N/A
IVA Inventiva	N/A	N/A	N/A	N/A	N/A
TNXP Tonix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AURA Aura Biosciences	N/A	12.39	11.06
CRVO CervoMed	N/A	8.20	9.78
IVA Inventiva	N/A	0.92	0.92
TNXP Tonix Pharmaceuticals	N/A	7.53	11.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AURA Aura Biosciences	96.75%
CRVO CervoMed	25.15%
IVA Inventiva	19.06%
TNXP Tonix Pharmaceuticals	82.26%

Insider Ownership

Company	Insider Ownership
AURA Aura Biosciences	6.30%
CRVO CervoMed	35.40%
IVA Inventiva	32.00%
TNXP Tonix Pharmaceuticals	0.03%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AURA Aura Biosciences	50	62.12 million	47.10 million	Not Optionable
CRVO CervoMed	4	9.25 million	5.98 million	Not Optionable
IVA Inventiva	100	95.66 million	65.05 million	Not Optionable
TNXP Tonix Pharmaceuticals	50	8.77 million	8.76 million	Not Optionable

CRVO, IVA, TNXP, and AURA Headlines

Recent News About These Companies

FDA approves first new fibromyalgia treatment in over 15 years

5 hours ago | thepharmaletter.comT

Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Gap Up - Time to Buy?

5 hours ago | marketbeat.com

Tonix Secures Fibromyalgia Approval - What Investors Should Know

August 16 at 9:11 AM | seekingalpha.com

Tonix Pharma Gains FDA Approval for Tonmya

August 16 at 2:38 AM | msn.com

Noble Financial Has Negative Estimate for TNXP Q3 Earnings

August 16 at 2:17 AM | americanbankingnews.com

Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia

August 15 at 8:37 PM | manilatimes.netM

Tonix Pharmaceuticals jumps 17% to $60.13 after FDA approval of Tonmya

August 15 at 8:37 PM | msn.com

Tonix Pharmaceuticals stock halted ahead of FDA approval news

August 15 at 8:37 PM | investing.com

Form 8K Tonix Pharmaceuticals Holding Corp For: 15 August

August 15 at 5:47 PM | investing.com

Tonix Pharmaceuticals (TNXP) Secures FDA Approval for Fibromyalgia Drug

August 15 at 5:12 PM | gurufocus.com

Tonix Pharmaceuticals Announces FDA Approval of Tonmya, the First New Fibromyalgia Therapy in Over 15 Years

August 15 at 4:22 PM | quiverquant.comQ

US FDA approves Tonix Pharma's drug to manage pain related to chronic condition

August 15 at 3:50 PM | reuters.com

Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia

August 15 at 3:44 PM | globenewswire.com

Tonix Pharma Gears Up For Key FDA Decision Today, Stock Up Over 500% In 5 Months

August 15 at 6:25 AM | rttnews.com

Companies Like Tonix Pharmaceuticals Holding (NASDAQ:TNXP) Are In A Position To Invest In Growth

August 14 at 11:42 PM | finance.yahoo.com

What's Going On With Tonix Pharmaceuticals (TNXP) Stock?

August 14 at 4:14 PM | benzinga.com

Caitong International Asset Management Co. Ltd Takes $405,000 Position in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)

August 14 at 7:07 AM | marketbeat.com

Tonix Pharma: Eyes On FDA Deadline This Friday, I See A 65% Approval Potential

August 13 at 1:07 PM | seekingalpha.com

Why Tonix Pharmaceuticals (TNXP) Stock Is Climbing This Week

August 13 at 11:17 AM | benzinga.com

Tonix Pharma Scores Best Day Since March On Hopes For First New Fibromyalgia Drug Approval in 16 Years; Retail’s Optimistic

August 13 at 2:35 AM | msn.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Posts Quarterly Earnings Results, Beats Estimates By $2.85 EPS

August 12, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CRVO, IVA, TNXP, and AURA Company Descriptions

Aura Biosciences NASDAQ:AURA

$6.72 -0.28 (-4.00%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$6.80 +0.08 (+1.19%)

As of 08/15/2025 07:13 PM Eastern

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

CervoMed NASDAQ:CRVO

$10.12 -0.07 (-0.69%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$10.00 -0.12 (-1.15%)

As of 08/15/2025 07:47 PM Eastern

CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

Inventiva NASDAQ:IVA

$4.36 +0.14 (+3.32%)

Closing price 08/15/2025 03:59 PM Eastern

Extended Trading

$4.32 -0.04 (-0.83%)

As of 08/15/2025 04:22 PM Eastern

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

Tonix Pharmaceuticals NASDAQ:TNXP

$51.43 -8.15 (-13.67%)

Closing price 08/15/2025 01:03 PM Eastern

Extended Trading

$56.96 +5.53 (+10.74%)

As of 08/15/2025 07:59 PM Eastern

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time